Japan Approves Blenrep Combos for Relapsed/Refractory Multiple Myeloma
GSK Secures Japanese Approval for Blenrep Combinations in Relapsed/Refractory Multiple Myeloma Based on Robust Phase III Data In a major advancement for the treatment landscape of multiple myeloma, GSK plc…
Regeneron to Acquire 23andMe for $256M, Will Keep Consumer Genetics Business
Regeneron to Acquire Core Assets of 23andMe for $256 Million in Bankruptcy Auction, Pledges to Preserve Consumer Genetics Mission and Strengthen Human Health Research In a major development within the…
BATURA Phase III Results Support Airsupra as Standard Rescue Treatment for Asthma
BATURA Phase IIIb Trial Establishes Airsupra as a New Standard for As-Needed Asthma Rescue Treatment AstraZeneca has released the full results from its pivotal BATURA Phase IIIb trial, revealing that…
Phase 3 Trial of Ifinatamab Deruxtecan Begins in Advanced Esophageal Cancer
Daiichi Sankyo and Merck Launch Phase 3 IDeate-Esophageal01 Trial of Ifinatamab Deruxtecan in Advanced Esophageal Squamous Cell Carcinoma Daiichi Sankyo and Merck have officially initiated dosing in their pivotal Phase…
Cytokinetics Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)
Cytokinetics Issues Equity Awards as Employment Inducements Under Nasdaq Rule 5635(c)(4), Advances Momentum in Cardiovascular Drug Development Cytokinetics, Incorporated (Nasdaq: CYTK), a leading biopharmaceutical company dedicated to developing novel therapies…
One World for Health: 78th World Health Assembly Set to Convene from 19–27 May 2025
One World for Health: Inside the 78th World Health Assembly and the Future of Global Public Health From May 19 to 27, 2025, Geneva, Switzerland, will once again become the…
WHO Partners with Universal Postal Union to Expand Global Access to Eyeglasses
WHO and Universal Postal Union Launch Global Initiative to Expand Access to Eye Care Through Postal Networks In a groundbreaking move to address the global burden of vision impairment, the…
30 Years of Progress: Mobilizing Health to End Violence Against Women and Girls
30 Years of Progress: Mobilizing the Health Sector to End Violence Against Women and Girls In the three decades since the landmark Beijing Platform for Action on Women was adopted…
BioMarin Strengthens Enzyme Capabilities Through $270 Million Acquisition of Inozyme
BioMarin Bolsters Enzyme Therapy Portfolio with $270 Million Acquisition of Rare Disease Specialist Inozyme Pharma BioMarin Pharmaceutical, a leading biotech company focused on rare diseases and enzyme replacement therapies, announced…
Incyte Secures FDA Approval for PD-1 Inhibitor in First-Line Treatment of Anal Cancer
Incyte’s Zynyz Secures First-Line Approval in Anal Cancer, Marking a Milestone for PD-1 Therapy in Rare Tumor Type In a significant development for the treatment of a rare and underserved…
Teen Scientists Win Over $9M at 75th Regeneron ISEF 2025
Global Youth Scientists Shine at 75th Regeneron ISEF, Sharing Over $9 Million in Prizes In a celebration of youthful brilliance, scientific curiosity, and international collaboration, the 75th Annual Regeneron International…
EU Approves Bristol Myers’ Opdivo Regimen for Resectable High-Risk NSCLC with PD-L1 ≥1%
European Commission Grants Approval to Bristol Myers Squibb’s Perioperative Opdivo Regimen for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% Bristol Myers Squibb has announced that the European Commission (EC) has…